Last 47 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.10 | — | — | — | — | — | — | — | — | — | — | — | — | 26.78 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.43 | 15.31 | 35.15 | 31.70 | 9.15 | 9.19 | 10.59 | 8.22 | 10.90 | 7.11 | 6.63 | 4.39 | 5.13 | 5.14 | 7.35 | 1.84 | 2.00 | 3.27 | 3.24 | 2.93 | 3.57 |
| — | +66.6% | +231.8% | +285.6% | -16.1% | +29.3% | +59.9% | +87.2% | +112.3% | +38.3% | -9.9% | +138.9% | +156.0% | +57.5% | +126.7% | -37.3% | -43.8% | -24.2% | -48.1% | -22.3% | -7.4% | |
| P/B Ratio | 3.72 | 5.31 | 5.01 | 5.43 | 3.96 | 10.43 | 5.36 | 6.17 | 5.54 | 8.06 | 5.67 | 2.97 | 2.97 | 2.81 | 3.36 | 7.83 | 28.10 | — | 29.40 | — | — |
| — | -49.1% | -6.6% | -12.0% | -28.6% | +29.4% | -5.5% | +107.8% | +86.9% | +186.8% | +69.1% | -62.1% | -89.4% | — | -88.6% | — | — | — | -3.2% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.70 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.44 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 4.17 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2% | 10.9% | 21.9% | 14.9% | 16.5% | 23.5% | 18.7% | 15.5% | 15.5% | 8.8% | 12.2% | 13.5% | 18.8% | 23.8% | 21.7% | 70.2% | 41.9% | 23.8% | 33.1% | 28.0% | 38.5% |
| — | -53.6% | +17.4% | -3.7% | +6.2% | +166.3% | +52.6% | +14.8% | -17.1% | -62.9% | -43.8% | -80.8% | -55.3% | -0.1% | -34.4% | +150.4% | +8.9% | -38.8% | -19.8% | -19.6% | -7.9% | |
| Operating Margin | -149.1% | -305.9% | -541.0% | -418.5% | -120.2% | -100.1% | -132.1% | -104.2% | -116.7% | -88.6% | -75.2% | -72.9% | -63.3% | -84.0% | -114.9% | 18.3% | -60.5% | -78.7% | -74.5% | -64.2% | -45.3% |
| — | -205.5% | -309.5% | -301.8% | -3.0% | -13.1% | -75.6% | -42.8% | -84.2% | -5.5% | +34.5% | -499.2% | -4.7% | -6.7% | -54.2% | +128.5% | -33.6% | -64.7% | -126.8% | -79.5% | -94.5% | |
| Net Margin | -140.8% | -239.1% | -200.1% | -384.7% | -48.8% | -233.3% | -18.4% | -66.9% | -236.1% | -124.5% | -196.0% | -32.7% | -46.0% | 19.2% | -97.2% | -64.2% | -72.4% | -93.3% | -81.4% | -75.8% | -52.5% |
| — | -2.5% | -990.3% | -474.9% | +79.3% | -87.4% | +90.6% | -104.9% | -413.5% | -748.9% | -101.6% | +49.1% | +36.5% | +120.6% | -19.4% | +15.3% | -37.8% | -76.8% | -67.0% | -192.1% | -82.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.9% | -19.2% | -6.9% | -15.3% | -7.5% | -51.8% | -2.3% | -12.0% | -39.5% | -30.7% | -35.5% | -5.4% | -6.5% | 2.7% | -16.7% | -118.6% | -253.6% | — | -184.5% | — | -515.8% |
| — | +63.0% | -198.4% | -28.1% | +80.9% | -68.8% | +93.4% | -121.7% | -510.9% | -1243.5% | -112.6% | +95.5% | +97.5% | — | +90.9% | — | +50.8% | — | -291.2% | — | -2435.6% | |
| ROA | -29.9% | -9.7% | -3.6% | -8.0% | -3.3% | -19.6% | -1.0% | -5.3% | -15.6% | -10.5% | -15.1% | -2.6% | -3.3% | 1.4% | -6.2% | -19.0% | -16.9% | -18.3% | -15.6% | -19.4% | -13.6% |
| — | +50.3% | -248.6% | -50.8% | +78.9% | -85.8% | +93.3% | -101.9% | -365.9% | -865.2% | -142.7% | +86.2% | +80.2% | +107.5% | +60.0% | +2.1% | -24.7% | -60.5% | -65.9% | -271.6% | -148.5% | |
| ROIC | -49.9% | -31.0% | -23.1% | -25.3% | -35.9% | -31.3% | -28.1% | -38.6% | -44.7% | -42.0% | -27.8% | -10.5% | -32.0% | — | — | — | — | — | — | — | — |
| — | +0.9% | +17.8% | +34.4% | +19.7% | +25.4% | -1.0% | -268.6% | -39.7% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.27 | 0.20 | 0.19 | 0.16 | 0.44 | 0.21 | 0.21 | 0.19 | 0.44 | 0.28 | 0.20 | 0.18 | 0.02 | 0.02 | 0.08 | 0.57 | — | 0.64 | — | — |
| — | -39.5% | -4.5% | -10.6% | -12.6% | +0.6% | -26.3% | +4.0% | +5.1% | +2166.9% | +1149.4% | +159.3% | -68.8% | — | -96.5% | — | — | — | +92.9% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.35 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.33 | 2.32 | 2.41 | 2.33 | 2.65 | 1.48 | 2.15 | 1.97 | 2.11 | 1.65 | 1.98 | 4.59 | 6.31 | 6.99 | 6.83 | 3.80 | 2.71 | 1.61 | 1.95 | 1.39 | 1.87 |
| — | +56.3% | +11.9% | +18.7% | +25.7% | -10.2% | +8.8% | -57.2% | -66.6% | -76.4% | -71.0% | +20.7% | +132.5% | +332.9% | +249.9% | +172.6% | +44.7% | -27.6% | -19.2% | -56.0% | -28.1% | |
| Quick Ratio | 2.17 | 2.09 | 2.19 | 2.17 | 2.48 | 1.35 | 1.99 | 1.86 | 1.99 | 1.51 | 1.83 | 4.33 | 5.88 | 6.61 | 6.56 | 3.64 | 2.50 | 1.42 | 1.78 | 1.28 | 1.75 |
| — | +55.2% | +10.1% | +16.6% | +24.7% | -10.5% | +8.7% | -56.9% | -66.2% | -77.2% | -72.1% | +18.9% | +134.6% | +364.8% | +268.1% | +183.7% | +43.2% | -31.7% | -21.6% | -57.3% | -28.7% | |
| Interest Coverage | -35.19 | -8.44 | — | — | — | -0.66 | — | — | -0.98 | -1.62 | -0.63 | — | — | -4.49 | — | -0.91 | -4.49 | -5.35 | -7.46 | -7.75 | -6.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDWD stock.
MediWound Ltd.'s current P/E is -9.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
MediWound Ltd.'s current operating margin is -149.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking MediWound Ltd.'s business trajectory between earnings reports.